Use of proteomic patterns in serum to identify ovarian cancer
- PMID: 11867112
- DOI: 10.1016/S0140-6736(02)07746-2
Use of proteomic patterns in serum to identify ovarian cancer
Abstract
Background: New technologies for the detection of early-stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary.
Methods: Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary "training" set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non-cancer. The discovered pattern was then used to classify an independent set of 116 masked serum samples: 50 from women with ovarian cancer, and 66 from unaffected women or those with non-malignant disorders.
Findings: The algorithm identified a cluster pattern that, in the training set, completely segregated cancer from non-cancer. The discriminatory pattern correctly identified all 50 ovarian cancer cases in the masked set, including all 18 stage I cases. Of the 66 cases of non-malignant disease, 63 were recognised as not cancer. This result yielded a sensitivity of 100% (95% CI 93--100), specificity of 95% (87--99), and positive predictive value of 94% (84--99).
Interpretation: These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for all stages of ovarian cancer in high-risk and general populations.
Comment in
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):169; author reply 170-1. doi: 10.1016/S0140-6736(02)09387-X. Lancet. 2002. PMID: 12126842 No abstract available.
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):169-70; author reply 170-1. doi: 10.1016/S0140-6736(02)09388-1. Lancet. 2002. PMID: 12126843 No abstract available.
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):170; author reply 170-1. doi: 10.1016/S0140-6736(02)09389-3. Lancet. 2002. PMID: 12126844 No abstract available.
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):170; author reply 170-1. doi: 10.1016/s0140-6736(02)09390-x. Lancet. 2002. PMID: 12126845 No abstract available.
-
Importance of disclosure of patent applications.Lancet. 2004 Aug 14-20;364(9434):577-8; author reply 578-9. doi: 10.1016/S0140-6736(04)16839-6. Lancet. 2004. PMID: 15313348 No abstract available.
-
Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit.Clin Chem. 2010 Oct;56(10):1641-2. doi: 10.1373/clinchem.2010.146142. Epub 2010 Jul 21. Clin Chem. 2010. PMID: 20660141 No abstract available.
Similar articles
-
Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.Clin Biochem. 2004 Sep;37(9):772-9. doi: 10.1016/j.clinbiochem.2004.04.002. Clin Biochem. 2004. PMID: 15329315
-
[Preliminary study on proteomic patterns in hepatic tissue to identify HBV related hepatocellular carcinoma].Zhonghua Gan Zang Bing Za Zhi. 2004 Apr;12(4):231-3. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 15099477 Chinese.
-
Progress and challenges in screening for early detection of ovarian cancer.Mol Cell Proteomics. 2004 Apr;3(4):355-66. doi: 10.1074/mcp.R400006-MCP200. Epub 2004 Feb 5. Mol Cell Proteomics. 2004. PMID: 14764655 Review.
-
Use of serological proteomic methods to find biomarkers associated with breast cancer.Proteomics. 2003 Apr;3(4):433-9. doi: 10.1002/pmic.200390058. Proteomics. 2003. PMID: 12687611
-
Clinical potential of proteomics in the diagnosis of ovarian cancer.Expert Rev Mol Diagn. 2002 Jul;2(4):312-20. doi: 10.1586/14737159.2.4.312. Expert Rev Mol Diagn. 2002. PMID: 12138495 Review.
Cited by
-
Proteomics appending a complementary dimension to precision oncotherapy.Comput Struct Biotechnol J. 2024 Apr 20;23:1725-1739. doi: 10.1016/j.csbj.2024.04.044. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38689716 Free PMC article. Review.
-
A Perspective Review: Analyzing Collagen Alterations in Ovarian Cancer by High-Resolution Optical Microscopy.Cancers (Basel). 2024 Apr 19;16(8):1560. doi: 10.3390/cancers16081560. Cancers (Basel). 2024. PMID: 38672642 Free PMC article. Review.
-
Origins, Technological Advancement, and Applications of Peptidomics.Methods Mol Biol. 2024;2758:3-47. doi: 10.1007/978-1-0716-3646-6_1. Methods Mol Biol. 2024. PMID: 38549006
-
A review on trends in development and translation of omics signatures in cancer.Comput Struct Biotechnol J. 2024 Feb 3;23:954-971. doi: 10.1016/j.csbj.2024.01.024. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38385061 Free PMC article. Review.
-
A personalized probabilistic approach to ovarian cancer diagnostics.Gynecol Oncol. 2024 Mar;182:168-175. doi: 10.1016/j.ygyno.2023.12.030. Epub 2024 Jan 23. Gynecol Oncol. 2024. PMID: 38266403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical